-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – HM-97662 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HM-97662 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HM-97662 in Solid Tumor Drug Details: HM-97662 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – HM-97662 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HM-97662 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HM-97662 in Non-Small Cell Lung Cancer Drug Details: HM-97662 is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – HM-01 in Chemotherapy Induced Peripheral Neuropathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HM-01 in Chemotherapy Induced Peripheral Neuropathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HM-01 in Chemotherapy Induced Peripheral Neuropathy Drug Details: HM-01 is...
-
Company Insights
Innovation and Patenting activity of HMS Networks AB Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of HMS Networks AB Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Company Insights
Innovation and Patenting activity of HMS Holdings Corp Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of HMS Holdings Corp Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HM-3 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HM-3 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HM-3 in Solid Tumor Drug Details: HM-3 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HM-21001 in Glioblastoma Multiforme (GBM)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.HM-21001 in Glioblastoma Multiforme (GBM) Drug Details:HM-21001 is under development for the treatment of glioblastoma multiforme....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HM-15912 in Short Bowel Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HM-15912 in Short Bowel Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.HM-15912 in Short Bowel Syndrome Drug Details:HM-15912 is under development for the...